Categories: "Viruses, Chronic & Infectious Diseases"
Reference #: 2011-052
A new compound class that may be used for the treatment of gram-positive bacterial infections has been discovered. The compounds have shown activity against a broad range of bacterial pathogens, including Staphylococcus saprophyticus, Staphylococcus aureus, Micrococcus sp., Enterococcus faecalis and Group A Streptococcus. Most importantly, the compounds are active against drug resistant strains, Methicillin Resistant Staphylococcus Aureus and Vancomycin Resistant Enterococcus faecalis.
The compounds may be useful against MRSA (methicillin resistant Staphylococcus aureus) and VRE (Vancomycin resistant Enterococcus). This is increasingly significant in light of the fact that emerging antibiotic resistance is a growing concern in hospital and community settings.
- Compounds have good activity against a range of bacterial pathogens
- Active against MRSA and VRE
- Minimal in vitro toxicity found
Stage of Development
Synthesis and screening has led to novel antibacterial compounds with activity against a range of bacterial pathogens, with minimal toxicity. Research is ongoing including lead compound optimization and structure activity relationship development.
No references or resources available.
Patents are currently pending covering compositions and methods of use.